Midazolam is a Small Molecule owned by UCB, and is involved in 6 clinical trials, which were completed.
Midazolam acts as a gamma aminobutyric acid receptor subunit alpha 1 (GABA1) agonist. Midazolam binds to the receptors result in opening of the chloride channel, resulting in a hyper-polarized cell membrane that prevents further excitation of the cell. This might increase the frequency of chloride channel opening resulting in neural inhibition.
Midazolam is a GABAA agonist. The drug candidate acts indirectly by enhancing the effect of the neurotransmitter GABA on the GABAA receptors. The drug candidate binds at the GABA receptors and increase the frequency of channel opening. This increases the affinity of GABA for its receptor. Consequently, this might increase the frequency of chloride channel opening resulting in neural inhibition. This might contribute to its anticonvulsant action.
The revenue for Midazolam is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Midazolam NPV Report.
Midazolam is currently owned by UCB.
Midazolam (Nayzilam) is a benzodiazepine derivative, acts as a short-acting hypnotic-sedative agent. It is formulated as spray for nasal route of administration. Midazolam is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older
Midazolam (USL-261) was under development for the treatment of epilepsy.
UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.
The company reported revenues of (Euro) EUR5,777 million for the fiscal year ended December 2021 (FY2021), an increase of 8% over FY2020. In FY2021, the company’s operating margin was 22.2%, compared to an operating margin of 18.2% in FY2020. In FY2021, the company recorded a net margin of 18.3%, compared to a net margin of 13.7% in FY2020.
Quick View – Midazolam
|Highest Development Stage|